Clinical trials
Mantle Cell Lymphoma clinical trials
Below are recruiting mantle cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 158 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT04491370RecruitingPhase 1/Phase 2
Stem cell transplant then polatuzumab for certain lymphomas
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
Valhalla, New YorkAges 12–70 - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04186520RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell lymphomas
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
Milwaukee, WisconsinAges 18–80 - NCT04223765RecruitingPhase 1
Testing a new CAR T-cell treatment for kappa cancers
This Phase 1 trial studies a lab-made immune therapy (CAR T cells) that targets “kappa” markers on certain lymphomas and CLL/SLL. It’s for people whose cancer has come back or didn’t respond to standard treatments, aiming to improve control of the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT03523975RecruitingPhase 1/Phase 2
Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Duarte, CaliforniaAges 18 years+ - NCT03501576Recruiting
Testing a flu or COVID vaccine response in people with lymphoma
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
Atlanta, GeorgiaAges 18 years+ - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06767891Enrolling by invitation
Acalabrutinib for mantle cell lymphoma or chronic lymphocytic leukemia
This study is looking at how well acalabrutinib works in real-world patients who have mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). If you have one of these types of blood cancer and have not had certain other treatments, you may be able to join.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07211048Recruiting
Gene therapy for B-cell lymphoma that hasn't responded to standard treatment
This trial tests a new gene therapy that re-engineers your own immune cells to attack CD19-positive lymphoma. It is for people whose B-cell lymphoma has come back or not responded to at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07398963RecruitingPhase 1
Virus-based CAR-T therapy for relapsed B-cell lymphoma
This trial uses a modified virus to deliver CAR-T cells directly into tumors, aiming to treat B-cell lymphoma that has come back or not responded to other treatments. It may be an option if your lymphoma is CD19-positive and you've tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT05992597RecruitingPhase 2
ZR2 follow-up immunotherapy for newly diagnosed mantle cell lymphoma
This trial tests a new combination of drugs (ZR2 followed by chemoinmunotherapy) for people newly diagnosed with mantle cell lymphoma. It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06496308RecruitingPhase 3
Adding orelabrutinib to standard therapy for mantle cell lymphoma
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
ShanghaiAges 18–80 - NCT06363994RecruitingPhase 3
Study of orelabrutinib plus BR for untreated mantle cell lymphoma
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
BeijingAges 60 years+ - NCT06697184RecruitingPhase 1/Phase 2
Testing a slower start of sonrotoclax for blood cancers
This trial tests a new way to slowly increase the dose of the drug sonrotoclax when starting treatment for blood cancers like chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). The goal is to see if this slower start is safer and better tolerated.
Tampa, FloridaAges 18 years+ - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT05724121Recruiting
Study heart rhythm changes during BTK or venetoclax treatment
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
Bethesda, MarylandAges 18–110 - NCT04368702Recruiting
MRI-guided radiation for people needing radiation for cancer
This study tests whether radiation given with help from MRI (a type of scan) can better treat cancers that need radiation. You may be eligible if your cancer is confirmed and you can safely have MRI scans.
Boston, MassachusettsAges 18 years+
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mantle cell lymphoma?
- Yes. Clin2 currently lists 158 recruiting mantle cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mantle cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mantle cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.